Boston Scientific Unveils Groundbreaking Data at NANS 2026

Boston Scientific Corporation recently showcased significant clinical data at the North American Neuromodulation Society (NANS) annual meeting in Las Vegas, Nevada, from January 22 to 25, 2026. The company presented a total of 17 abstracts, which included seven oral presentations focusing on chronic pain and deep brain stimulation therapies.

The findings shared at this year’s conference contribute to the extensive evidence supporting the effectiveness of Boston Scientific’s spinal cord stimulation therapies. Jim Cassidy, president of Neuromodulation at Boston Scientific, remarked, “The data presented at this year’s NANS add to the growing body of evidence for our spinal cord stimulation therapies and underscore our category leadership in the pain space.” He emphasized the company’s commitment to investing in long-term science and innovation, aiming to provide physicians with more personalized and proven treatment options for their patients.

Highlighting Innovations in Pain Management

During the event, Boston Scientific also highlighted the Intracept EDGE J Stylet, a key instrument associated with its Intracept Intraosseous Nerve Ablation System. This advanced tool is engineered to optimize access to the basivertebral nerve, thereby enhancing the treatment experience for patients suffering from vertebrogenic low back pain. The Intracept procedure is notable for being the first device-based therapy in the United States cleared by the FDA for this specific type of pain, showcasing its potential to deliver improved functionality and long-term relief.

Attendees at the NANS meeting were invited to explore this latest innovation at booth #131, where they could engage with a hands-on simulator experience. This interactive feature is designed to demonstrate the practical applications of the technology and its benefits in clinical settings.

For those interested in a comprehensive overview of Boston Scientific’s clinical and scientific data presentations at NANS 2026, further details are available on the company’s dedicated webpage: NANS 2026 – Boston Scientific.

Boston Scientific’s participation in this prestigious meeting underscores its ongoing efforts to lead in the neuromodulation field, promising advancements that could significantly enhance patient outcomes in pain management.